EUVIMEDEUVIMED entdecken
Open Access

BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir

Wen-Fang Tang, Yu-Hsiu Chang, Cheng-Chin Lin, Jia-Rong Jheng, Chung-Fan Hsieh, Yuan-Fan Chin, Tein-Yao Chang, Jin-Ching Lee, Po-Huang Liang iD, Chia-Yi Lin, Guan-Hua Lin, Jie-Yun Cai und 17 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00956-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Wen-Fang Tang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Kweishan, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Quinolines, Pyrazoles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Chang Gung Memorial Hospital (CGMH), National Science and Technology Council (NSTC), The Ministry of Education and the National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral RNA-dependent RNA polymerase (RdRp), a highly conserved molecule in RNA viruses, has recently emerged as a promising drug target for broad-acting inhibitors. Through a Vero E6-based anti-cytopathic effect assay, we found that BPR3P0128, which incorporates a quinoline core similar to hydroxychloroquine, outperformed the adenosine analog remdesivir in inhibiting RdRp activity (EC 50 = 0.66 µM and 3 µM, respectively). BPR3P0128 demonstrated broad-spectrum activity against various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. When introduced after viral adsorption, BPR3P0128 significantly decreased SARS-CoV-2 replication; however, it did not affect the early entry stage, as evidenced by a time-of-drug-addition assay. This suggests that BPR3P0128’s primary action takes place during viral replication. We also found that BPR3P0128 effectively reduced the expression of proinflammatory cytokines in human lung epithelial Calu-3 cells infected with SARS-CoV-2. Molecular docking analysis showed that BPR3P0128 targets the RdRp channel, inhibiting substrate entry, which implies it operates differently—but complementary—with remdesivir. Utilizing an optimized cell-based minigenome RdRp reporter assay, we confirmed that BPR3P0128 exhibited potent inhibitory activity. However, an enzyme-based RdRp assay employing purified recombinant nsp12/nsp7/nsp8 failed to corroborate this inhibitory activity. This suggests that BPR3P0128 may inhibit activity by targeting host-related RdRp-associated factors. Moreover, we discovered that a combination of BPR3P0128 and remdesivir had a synergistic effect—a result likely due to both drugs interacting with separate domains of the RdRp. This novel synergy between the two drugs reinforces the potential clinical value of the BPR3P0128-remdesivir combination in combating various SARS-CoV-2 variants of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19QuinolinesPyrazolesHumansSARS-CoV-2RNA-Dependent RNA PolymeraseMolecular Docking SimulationCOVID-19 Drug TreatmentAdenosine MonophosphateAlanineAntiviral Agents

Stichwörter der Autor:innen

BPR3P0128RdRp reporter assaySARS-CoV-2antiviralbroad-spectrum antiviralremdesivirsynergistic effect

Substanzen

remdesivirRNA-Dependent RNA PolymeraseBPR3P0128Adenosine MonophosphateQuinolinesAlanineAntiviral AgentsPyrazoles

Autor:innen und Institutionen

  • Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Kweishan, Taoyuan, Taiwan.
  • Institute of Preventive Medicine, National Defense Medical Center, New Taipei, Taiwan.
  • Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan.
  • Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Kweishan, Taoyuan, Taiwan.
  • Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

ORCID-Profile: Po-Huang Liang, Hui-Ping Tsai, Jim-Tong Horng

Förderung

  • Chang Gung Memorial Hospital (CGMH)
  • National Science and Technology Council (NSTC)
  • The Ministry of Education and the National Science and Technology Council
  • Academia Sinica (AS)

Zitieren

APA

Tang, W. F., Chang, Y. H., Lin, C. C., Jheng, J. R., Hsieh, C. F., Chin, Y. F., Chang, T. Y., Lee, J. C., Liang, P. H., Lin, C. Y., Lin, G. H., Cai, J. Y., Chen, Y. L., Chen, Y. S., Tsai, S. K., Liu, P. C., Yang, C. M., Shadbahr, T., Tang, J., …, & Horng, J. T. (2024). BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00956-23

Vancouver

Tang WF, Chang YH, Lin CC, Jheng JR, Hsieh CF, Chin YF, et al. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00956-23

BibTeX
@article{Tang2024,
  author = {Tang, Wen-Fang and Chang, Yu-Hsiu and Lin, Cheng-Chin and Jheng, Jia-Rong and Hsieh, Chung-Fan and Chin, Yuan-Fan and Chang, Tein-Yao and Lee, Jin-Ching and Liang, Po-Huang and Lin, Chia-Yi and Lin, Guan-Hua and Cai, Jie-Yun and Chen, Yu-Li and Chen, Yuan-Siao and Tsai, Shan-Ko and Liu, Ping-Cheng and Yang, Chuen-Mi and Shadbahr, Tolou and Tang, Jing and Hsu, Yu-Lin and Huang, Chih-Heng and Wang, Ling-Yu and Chen, Cheng Cheung and Kau, Jyh-Hwa and Hung, Yi-Jen and Lee, Hsin-Yi and Wang, Wen-Chieh and Tsai, Hui-Ping and Horng, Jim-Tong},
  title = {BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00956-23}
}
Kostenlos starten →